Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer

Wang, Xiao-Shan; Bai, Yi-Feng; Verma, Vivek; Yu, Rui-Lian; Tian, Wei; Ao, Rui; Deng, Ying; Zhu, Xue-Qiang; Liu, Hao; Pan, Hai-Xia; Yang, Lan; Bai, Han-Song; Luo, Xing; Guo, Yan; Zhou, Ming-Xiu; Sun, Yue-Mei; Zhang, Zi-Can; Li, Si-Min; Cheng, Xue; Tan, Bang-Xian; Han, Liang-Fu; Liu, Ying-Yi; Zhang, Kai; Zeng, Fan-Xin; Jia, Lin; Hao, Xin-Bao; Wang, You-Yu; Feng, Gang; Xie, Ke; Lu, You; Zeng, Ming

doi:10.1093/jnci/djac015

Public

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer

Shared by NobleBlocks on Jan 28, 2022 • 12:00 AM UTC

Authors:

Xiao-Shan Wang

Yi-Feng Bai

Vivek Verma

Abstract

Abstract Background Adding radiotherapy (RT) to systemic therapy improves progression-free survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer (NSCLC). Whether these findings translate to epidermal growth factor receptor (EGFR)–mutated NSCLC remains unknown. The SI...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!